Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Accured Expenses: 2013-2025

Historic Change in Accured Expenses for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Change in Accured Expenses rose 391.95% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 521.98%. This contributed to the annual value of $1.5 million for FY2024, which is 120.69% up from last year.
  • As of Q3 2025, Theravance Biopharma's Change in Accured Expenses stood at $3.6 million, which was up 12.97% from $3.2 million recorded in Q2 2025.
  • Theravance Biopharma's Change in Accured Expenses' 5-year high stood at $4.4 million during Q4 2022, with a 5-year trough of -$17.3 million in Q1 2021.
  • For the 3-year period, Theravance Biopharma's Change in Accured Expenses averaged around -$31,182, with its median value being -$123,000 (2023).
  • As far as peak fluctuations go, Theravance Biopharma's Change in Accured Expenses plummeted by 429.98% in 2021, and later soared by 782.88% in 2024.
  • Over the past 5 years, Theravance Biopharma's Change in Accured Expenses (Quarterly) stood at -$652,000 in 2021, then spiked by 771.63% to $4.4 million in 2022, then tumbled by 110.00% to -$438,000 in 2023, then surged by 782.88% to $3.0 million in 2024, then surged by 391.95% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $3.2 million for Q2 2025, and -$1.5 million during Q1 2025.